Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses

  • Nicola Amedeo Mazzanti AstraZeneca, Milano, Italy
  • Carolina Scauri AstraZeneca, Milano, Italy
  • Bianca Domini EY Advisory S.p.A., Milano, Italy
  • Chiara Vassallo EY Advisory S.p.A., Milano, Italy
  • Simone Cusato EY Advisory S.p.A., Roma, Italy
  • Chiara De Fino EY Advisory S.p.A., Milano, Italy
  • Filippo de Marinis Oncologia Toracica, IEO, IRCCS, Milano, Italy
Keywords: Osimertinib, tyrosine kinase inhibitors (TKI), non-small cell lung cancer (NSCLC), economic evaluation, cost analysis

Abstract

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are established therapies for previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) EGFR-mutated patients. Osimertinib, a third-generation TKI, has recently received the same first-line indication. This study aims at investigating management costs and potential productivity losses in Italy in this patient setting, given all the available therapeutic options. Two analyses were performed. The first evaluates first-line yearly management costs and potential productivity losses per patient, for each first-line treatment. The second, performed nationally and regionally, models all lines of treatments and costs over a five-year period, through different market-share scenarios – considering osimertinib adoption as new therapy in 60% of patients as the most probable one – and line-switch/mortality probabilities. Using this model, patients’ total months of treatment and development/progression of brain metastases were also analyzed. The first analysis shows that first-line management costs and potential productivity losses are minimized by osimertinib (first-line yearly expenditure of €25.942, 8%-12% less than TKIs). The second analysis, based on a five-year horizon and on all therapy lines, shows that total management costs and potential productivity losses decrease by increasing the adoption of osimertinib as a first-line therapy (€7.4m cumulative lower cost with osimertinib at 60% compared to 0%). Considering the average month of therapy, where results are not affected by the length of the therapy, with osimertinib at 60% on naïve patients, monthly management costs and productivity losses are 10% lower than in the non-osimertinib scenario. In advanced, metastatic EGFR-mutated NSCLC, the use of osimertinib as the first-line treatment could reduce patient management costs and potential productivity losses.
Published
2019-10-08
How to Cite
MazzantiN. A., ScauriC., DominiB., VassalloC., CusatoS., De FinoC., & de MarinisF. (2019). Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses. Global & Regional Health Technology Assessment, 6(1). https://doi.org/10.33393/grhta.2019.451
Section
Original Research Article